

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/252669 A1

(51) International Patent Classification:

A61K 31/426 (2006.01) A61P 5/38 (2006.01)

A61K 31/573 (2006.01) A61K 9/00 (2006.01)

(21) International Application Number:

PCT/US2021/036668

(22) International Filing Date:

09 June 2021 (09.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

FR2006039 10 June 2020 (10.06.2020) FR

(71) Applicants: **NEUROCRINE BIOSCIENCES, INC.**

[US/US]; 12780 El Camino Real, San Diego, California 92130 (US). **SANOFI** [FR/FR]; 54 rue de la Boétie, 75008 Paris (FR).

(72) Inventors: **FARBER, Robert H.**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **CHAN, Jean L.**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **ROBERTS, Eiry**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **CUTLER, JR., Gordon B.**; 630 Bland Point Rd., Deltaville, Virginia 23043-2172 (US). **NAKANISHI, Arline**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **CHARLIER, Anne**; c/o Sanofi, Patent Department, 54 rue de la Boétie, 75008 Paris (FR). **LOEWEN, Gordon RAPHAEL**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **ZHANG, Xiaoping**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **GIRI, Nagdeep**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **STIRN, Scott**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **SAYERS, Brian**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **TAYLOR, Graeme**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **COSTA, Christina MARIE**; c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, California 92130 (US). **PARKS, Stacy**; c/o Bend Research, Inc., 63045 NE Corporate Pl., Bend, Oregon 97701 (US). **VICKERY, Anthony D.**; c/o Bend Research, Inc., 63045 NE Corporate Pl., Bend, Oregon 97701 (US). **DOWNING, Kristie M.**; c/o Bend Research, Inc., 63045 NE Corporate Pl., Bend, Oregon 97701 (US). **IYOH, Kingsley**; c/o Quotient Sciences Limited, Trent House, Mere Way, Ruddington, Nottingham Nottinghamshire NG11 6JS (GB). **NG-**

WENYA-JONES, Ayanda; c/o Quotient Sciences Limited, Trent House, Mere Way, Ruddington, Nottingham Nottinghamshire NG11 6JS (GB). **MEHTON, Gurvinder**; c/o Quotient Sciences Limited, Trent House, Mere Way, Ruddington, Nottingham Nottinghamshire NG11 6JS (GB).

(74) Agent: **BOYLE, Craig D.** et al.; P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: CRF1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA

(57) Abstract: Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering to the subject a compound of Formula (I): [INSERT FORMULA] (I), or a pharmaceutically acceptable salt thereof.



WO 2021/252669 A1